| Coagulation index to distinguish severe preeclampsia from normal pregnancy. | |
| | |
MedLine Citation:
|
PMID: 12536338 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to establish a new coagulation index to distinguish severe preeclampsia from normal pregnancy using optimal coagulation parameters. The difference between platelet counts in early gestation and before delivery (DeltaPlt = [platelet counts before delivery] - [platelet counts in early gestation]) was calculated as an index of changes in platelet counts. Antithrombin (AT) activity, thrombin-antithrombin (TAT) complex, fibrin degradation products (FDP) D-dimer, and DeltaPlt were investigated in 72 cases of normal pregnant women in the third trimester of pregnancy and 56 cases of severe preeclampsia. The new coagulation index was calculated using multivariate logistic regression analysis. As a result, in a case using four parameters, the following formula was obtained: Y = (-0.019 x AT activity) + (0.067 x TAT) + (0.067 x D-dimer) + (-0.064 x DeltaPlt) + 0.706. According to this formula, coagulation indices in normal pregnant women and in patients with severe preeclampsia were -0.77 +/- 0.51 and 1.41 +/- 1.56, respectively (p < 0.0001). Among patients with severe preeclampsia, coagulation and fibrinolysis disorders before delivery were typical in patients terminated by cesarean section (coagulation index = 1.62 +/- 1.66) compared with those with successful vaginal delivery (coagulation index = 0.52 +/- 0.34) (p < 0.05). These facts suggest that an excessive hypercoagulable state is associated with the termination of pregnancy resulting from the aggravation of preeclampsia. From the viewpoint of coagulation and fibrinolysis disorders, the predictive value in order to decide the optimal time for the termination of pregnancy could be recommended when the coagulation index exceeded 1.20. |
| | |
Authors:
|
Takao Kobayashi; Kazuhiro Sumimoto; Naoki Tokunaga; Motoi Sugimura; Tomizo Nishiguchi; Naohiro Kanayama; Toshihiko Terao |
Related Documents
:
|
15214708 - Termination of multiple pregnancy at 18-24 weeks' gestation by laminaria dilatation and... 2036798 - Embryotoxicity and teratogenicity of dl111-it, an early pregnancy-terminating agent, in... 7050298 - Influence of low oxygen concentration on derepression of nitrogenase in klebsiella pneu... 12959148 - Early medical termination pregnancy with methotrexate and misoprostol in lower segment ... 15214708 - Termination of multiple pregnancy at 18-24 weeks' gestation by laminaria dilatation and... 6333658 - Premature rupture of membranes before fetal viability. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Seminars in thrombosis and hemostasis Volume: 28 ISSN: 0094-6176 ISO Abbreviation: Semin. Thromb. Hemost. Publication Date: 2002 Dec |
Date Detail:
|
Created Date: 2003-01-21 Completed Date: 2003-06-25 Revised Date: 2006-03-07 |
Medline Journal Info:
|
Nlm Unique ID: 0431155 Medline TA: Semin Thromb Hemost Country: United States |
Other Details:
|
Languages: eng Pagination: 495-500 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu City, Shizuoka, 431-3192 Japan. tkoba@hama-med.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antithrombins
/
metabolism Blood Coagulation* Blood Coagulation Tests / methods Case-Control Studies Female Fibrin Fibrinogen Degradation Products / metabolism Fibrinolysis Humans Labor, Induced Multivariate Analysis Platelet Count Pre-Eclampsia / blood*, diagnosis, therapy Pregnancy Thrombin / metabolism Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antithrombins; 0/Fibrin Fibrinogen Degradation Products; EC 3.4.21.5/Thrombin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Scorecard endoscopy: a pilot study to assess basic skills in trainees for upper gastrointestinal end...
Next Document: The M235T variant of the angiotensinogen gene and the body mass index are useful markers for prevent...